Phaseline

Companies › Suzhou Siran Biotechnology

Suzhou Siran Biotechnology: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 1; Metabolic and endocrine, Infectious disease; next expected readout Mar 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
SA1211 injection
unclear - unknown biologic
–Phase 1Chronic Hepatitis BMar 2027
SA030 Injection–Phase 1ObeseApr 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07275918SA1211 injectionPhase 1Chronic Hepatitis BInfectious diseaseMar 2027
NCT07479862SA030 InjectionPhase 1ObeseMetabolic and endocrineApr 2028

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.